R-CHOP治疗非人类免疫缺陷病毒感染的非霍奇金b细胞淋巴瘤肺囊虫性肺炎的研究进展

IF 0.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI:10.36468/pharmaceutical-sciences.1185
Fengping Zhou, Shenhe Jin, Jin Zhang
{"title":"R-CHOP治疗非人类免疫缺陷病毒感染的非霍奇金b细胞淋巴瘤肺囊虫性肺炎的研究进展","authors":"Fengping Zhou, Shenhe Jin, Jin Zhang","doi":"10.36468/pharmaceutical-sciences.1185","DOIUrl":null,"url":null,"abstract":"Increasing numbers of non-human immunodeficiency virus-infected individuals with non-Hodgkin's B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone have been diagnosed with Pneumocystis pneumonia. Pneumocystis pneumonia is a serious infection with a high mortality rate and rapid progression. In these patients, the incidence of Pneumocystis pneumonia varied from 1.4 % to 13 %, according to a comprehensive literature review. The major clinical symptoms were dry cough, fever, tightness in the chest, progressive dyspnea and hypoxemia. The standard method of diagnosis is Pneumocystis detection in broncho alveolar lavage fluid and high-resolution computed tomography can be detected in diffuse interstitial infiltration of both lungs. Trimethoprim/sulfamethoxazole is the main treatment for Pneumocystis pneumonia and most studies have shown that preventive use of trimethoprim/ sulfamethoxazole can help reduce the incidence of Pneumocystis pneumonia. In order to improve the accuracy of diagnosis and the prompt initiation of therapy for treatment and prevention to improve outcomes in these patients, a deeper knowledge of the relationship between rituximab use and the incidence of Pneumocystis pneumonia and the characteristics of Pneumocystis pneumonia in non-human immunodeficiency virusinfected patients with lymphoma is required.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"266 1","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress in the Research of Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Non-Hodgkin's B-Cell Lymphoma Treated With R-CHOP\",\"authors\":\"Fengping Zhou, Shenhe Jin, Jin Zhang\",\"doi\":\"10.36468/pharmaceutical-sciences.1185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Increasing numbers of non-human immunodeficiency virus-infected individuals with non-Hodgkin's B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone have been diagnosed with Pneumocystis pneumonia. Pneumocystis pneumonia is a serious infection with a high mortality rate and rapid progression. In these patients, the incidence of Pneumocystis pneumonia varied from 1.4 % to 13 %, according to a comprehensive literature review. The major clinical symptoms were dry cough, fever, tightness in the chest, progressive dyspnea and hypoxemia. The standard method of diagnosis is Pneumocystis detection in broncho alveolar lavage fluid and high-resolution computed tomography can be detected in diffuse interstitial infiltration of both lungs. Trimethoprim/sulfamethoxazole is the main treatment for Pneumocystis pneumonia and most studies have shown that preventive use of trimethoprim/ sulfamethoxazole can help reduce the incidence of Pneumocystis pneumonia. In order to improve the accuracy of diagnosis and the prompt initiation of therapy for treatment and prevention to improve outcomes in these patients, a deeper knowledge of the relationship between rituximab use and the incidence of Pneumocystis pneumonia and the characteristics of Pneumocystis pneumonia in non-human immunodeficiency virusinfected patients with lymphoma is required.\",\"PeriodicalId\":13292,\"journal\":{\"name\":\"Indian Journal of Pharmaceutical Sciences\",\"volume\":\"266 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36468/pharmaceutical-sciences.1185\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36468/pharmaceutical-sciences.1185","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

越来越多的非人类免疫缺陷病毒感染的非霍奇金B细胞淋巴瘤患者接受利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和强的松治疗后被诊断为肺囊虫性肺炎。肺囊虫性肺炎是一种死亡率高、进展快的严重感染。在这些患者中,肺囊虫肺炎的发病率从1.4%到13%不等,根据全面的文献综述。主要临床症状为干咳、发热、胸闷、进行性呼吸困难、低氧血症。诊断的标准方法是在支气管肺泡灌洗液中检测肺囊虫,双肺弥漫性间质浸润可检测高分辨率计算机断层扫描。甲氧苄啶/磺胺甲恶唑是肺囊虫肺炎的主要治疗药物,大多数研究表明,预防性使用甲氧苄啶/磺胺甲恶唑有助于减少肺囊虫肺炎的发病率。为了提高诊断的准确性,及时开始治疗和预防,以改善这些患者的预后,需要更深入地了解利妥昔单抗与肺囊虫肺炎发病率的关系,以及非人类免疫缺陷病毒感染的淋巴瘤患者肺囊虫肺炎的特征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Progress in the Research of Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Non-Hodgkin's B-Cell Lymphoma Treated With R-CHOP
Increasing numbers of non-human immunodeficiency virus-infected individuals with non-Hodgkin's B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone have been diagnosed with Pneumocystis pneumonia. Pneumocystis pneumonia is a serious infection with a high mortality rate and rapid progression. In these patients, the incidence of Pneumocystis pneumonia varied from 1.4 % to 13 %, according to a comprehensive literature review. The major clinical symptoms were dry cough, fever, tightness in the chest, progressive dyspnea and hypoxemia. The standard method of diagnosis is Pneumocystis detection in broncho alveolar lavage fluid and high-resolution computed tomography can be detected in diffuse interstitial infiltration of both lungs. Trimethoprim/sulfamethoxazole is the main treatment for Pneumocystis pneumonia and most studies have shown that preventive use of trimethoprim/ sulfamethoxazole can help reduce the incidence of Pneumocystis pneumonia. In order to improve the accuracy of diagnosis and the prompt initiation of therapy for treatment and prevention to improve outcomes in these patients, a deeper knowledge of the relationship between rituximab use and the incidence of Pneumocystis pneumonia and the characteristics of Pneumocystis pneumonia in non-human immunodeficiency virusinfected patients with lymphoma is required.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
2 months
期刊介绍: The Indian Journal of Pharmaceutical Sciences (IJPS) is a bi-monthly Journal, which publishes original research work that contributes significantly to further the scientific knowledge in Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Therapeutics, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, Drug Information, Patient Counselling, Adverse Drug Reactions Monitoring, Medication Errors, Medication Optimization, Medication Therapy Management, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). The Journal publishes original research work either as a Full Research Paper or as a Short Communication. Review Articles on current topics in Pharmaceutical Sciences are also considered for publication by the Journal.
期刊最新文献
Phytochemicals, Antioxidant and Antimicrobial Potential of Ethnomedicinal Plants of Sikkim Himalaya Synthesis, Cannabinoid Receptor Targeted Molecular Docking of Some New Pyrazole Derivatives as Hypolipidemic and Anti- Obesity Agents Bioassay Guided Isolation of Anti-Inflammatory Compounds from Bauhinia variegata L.: A Key Ingredient in Herbo-Mineral Formulation, Gandmala Kandan Ras Network Pharmacology Prediction to Explore the Potential Mechanism of Qing'E Pills Effects of Oleanolic Acid on Myocardial Injury in Diabetic Mice by Regulating Phosphatidylinositol 3 Kinase/Protein Kinase B/Glucose Transporter Type 4 Signalling Pathway
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1